Investigational drug · Phase 2
NEO100
Also called: Perillyl alcohol
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma Multiforme, Residual, Progressive or Recurrent Grade II or III Meningioma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "NEO100"
First trial start
2017
Aug 1, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NEO100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma Multiforme
- Residual, Progressive or Recurrent Grade II or III Meningioma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NEO100" as an intervention, largest first.
Neonc Technologies, Inc.Industry
NCT06047379 · 134 participants (planned) · Start Nov 1, 2023 · Primary completion Feb 28, 2027
Drug: NEO212 Oral Capsule; Ipilimumab and 7 more · For: Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult and 18 more
Sites: Beverly Hills, California; Glendale, California; Los Angeles, California · 8 sites in all
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaActive, not recruiting
Neonc Technologies, Inc.Industry
NCT02704858 · 49 participants (planned) · Start Aug 1, 2017 · Primary completion Nov 30, 2026
Drug: Perillyl alcohol · For: Glioblastoma Multiforme
Sites: Los Angeles, California; San Francisco, California; Santa Monica, California · 11 sites in all
- NEO100 and High-Grade MeningiomaRecruiting
Neonc Technologies, Inc.Industry
NCT05023018 · 30 participants (planned) · Start Jul 1, 2022 · Primary completion Dec 30, 2026
Drug: NEO100 · For: Residual, Progressive or Recurrent Grade II or III Meningioma
Sites: Los Angeles, California; San Francisco, California; Santa Monica, California · 5 sites in all
- A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsRecruiting
Neonc Technologies, Inc.Industry
NCT06357377 · 12 participants (planned) · Start Sep 8, 2026 · Primary completion Jun 2027
Drug: NEO100 · For: Pediatric Tumor of CNS; Pediatric Tumor of Brain; Diffuse Midline Glioma, H3 K27M-Mutant and 5 more
Sites: Orange, California
Newest research
PubMed records naming it or its code names, newest first.
- Identification of potential active ingredients from Chuanxiong Rhizoma in the treatment of vascular dementia: CHI3L1 and TLR2 are potential key targets.
Liao H, Zeng Q, Zhang J, et al. · Medicine (Baltimore) 2026
- Terpenoid Modulation of ?-Aminobutyric Acid Receptors Type A in Oocytes and General Anesthetic Activity in Rats.
Brosnan RJ, Shafeinia M, Aguiar AJA, et al. · Pharmacology 2026
- It takes two: development of simulation training for two-handed neonatal mask ventilation integrating a respiratory function monitor; a non-randomised before-and-after simulation study.
Ryan LJ, Murphy E, Smiles L, et al. · Resusc Plus 2026
- Electrospun zein nanofibres incorporating NADES-phytochemical systems as sustainable antimicrobial wound dressings.
Silva SM, Afonso A, Simões M, et al. · Int J Biol Macromol 2026
- Developing cumate-inducible gene expression systems for application in Pseudomonas putida KT2440.
Liu CL, Di X, Niu S, et al. · J Appl Microbiol 2026
- Synthesis and Antifungal Activities of Perillyl Alcohol Based 1,3,4-Thiadiazole-Thioether Compounds.
Xiong Y, Zhang Y, Cui Y, et al. · Chem Biodivers 2026
Also in development for Glioblastoma Multiforme
- LAM561Phase 32 trials
Laminar Pharmaceuticals · Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma
- APL-101Phase 21 trial
Apollomics Inc. · Solid Tumors, Advanced Cancer, Renal Cancer
- BPM31510Phase 21 trial
BPGbio · Glioblastoma, Glioblastoma Multiforme
- NG101mPhase 21 trial
NeuGATE Theranostics · Glioblastoma Multiforme
- ST101Phase 21 trial
Sapience Therapeutics · Glioblastoma, Melanoma Stage IV, Breast Cancer
- VAL-083Phase 21 trial
Kintara Therapeutics, Inc. · Glioma, Glioblastoma, Glioblastoma Multiforme
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.